Cholesterol drug from Sanofi/Regeneron gains US CV risk redu...
Sanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a new indication that will help it compete with Amgen’s rival from the sa
